HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Royal Commission on nano

This article was originally published in The Rose Sheet

Executive Summary

There is no evidence of environmental or health risks from nanomaterials, and thus no need for a ban or moratorium against nanotechnology, the U.K.'s Royal Commission on Environmental Pollution says in a report published Nov. 12. However, the independent advisory panel calls for more testing on the functionality of nanoparticles, the immediate establishment of a research program and more flexibility in government to address nanotechnology and other nascent fields. Sir John Lawton, commission chair, calls for extending the coverage of the EU's REACH chemical regulation to nanomaterials, as "the rate of innovation in this sector far outstrips our capacity to respond to the risks." The European Commission has advised EU members to refrain from research on nanoparticles in food and personal care items until more risk assessments are completed (1"The Rose Sheet" Feb. 18, 2008, p. 6)

You may also be interested in...

EC Advises Against Studying Nano-Cosmetics In Humans Until Risks Are Known

Researchers should avoid clinical studies on nano-based cosmetics until more is known about their long-term effects, according to a Recommendation issued Feb. 7 by the European Commission (EC)

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts